Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
51 Results Found
Cost-Plus Drug Pricing Models Gain Momentum, but Will They Last?
CVS Health plans to launch its CVS CostVantage and CVS Caremark TrueCost programs in 2025. CostVantage will define the drug cost and related reimbursement with contracted PBMs and payers, CVS noted in a statement.
Affordability Advocacy Agenda
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The American Hospital Association continues to incorporate principles that promote improved affordability, value, and equity into our policy and advocacy activities.
Report: Most hospitals, health plans posting machine-readable price transparency data
About 84% of hospitals had posted a machine-readable file containing rate information by the end of first-quarter 2023, up from 65% the previous quarter, according to a report released by Turquoise Health.
Mark Cuban Lays Out More Details about How He’s Disrupting Drug Pricing
It’s no secret that billionaire Mark Cuban has his mind and assets focused on disrupting drug pricing in the U.S. But during a recent talk, Cuban shared new information about what his Cost Plus Drugs company is doing with payers and pharmacists.
CMS to test new models to lower drug costs
The CMS Innovation Center will test three new models to see whether they lower high drug costs, the Centers for Medicare & Medicaid Services announced yesterday.
CMS proposes to require drug manufacturers to disclose prices in ads
The Centers for Medicare & Medicaid Services today issued a proposed rule aimed at increasing drug pr
Will Startup PBMs Drive Drug Price Transparency?
The Purchaser Business Group on Health (PBGH), a coalition of about 40 large private and public employers including Walmart, Disney, Costco and Microsoft, recently launched EmsanaRx, a nonprofit PBM. Meanwhile, billionaire Mark Cuban’s Cost Plus Drug Company is another PBM that launched recently.
AHA Senate Statement: “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare”
AHA shares proposals to lower Medicare drug prices with congress.
Senate holds hearing on anticompetitive drugmaker conduct
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing on surging drug prices and anticompetitive conduct in the pharmaceutical industry.
AHA expresses support for Drug-Price Transparency for Consumers Act
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).